Cyclophosphamide - NDC Database (Page 4)
51407-750 Nov 19, 2021
Cyclophosphamide 200 mg/ml Intravenous Injection, Solution by Golden State Medical Supply, Inc.
Cyclophosphamide 200 mg/ml Intravenous Injection, Solution by Golden State Medical Supply, Inc.
65219-131 Nov 17, 2023
Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Fresenius Kabi USA, LLC
Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Fresenius Kabi USA, LLC
65219-133 Nov 17, 2023
Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Fresenius Kabi USA, LLC
Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Fresenius Kabi USA, LLC
65219-135 Nov 17, 2023
Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Fresenius Kabi USA, LLC
Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Fresenius Kabi USA, LLC
68001-370 May 31, 2018
Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Bluepoint Laboratories
Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Bluepoint Laboratories
68001-371 May 31, 2018
Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Bluepoint Laboratories
Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Bluepoint Laboratories
68001-372 May 31, 2018
Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Bluepoint Laboratories
Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Bluepoint Laboratories
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.